REDEFINE 1 analyses presented at The Menopause Society 2026 meeting found mean weight loss of 23.1% to 26.7% across pre-, peri-, and postmenopausal women.
|Articles|January 6, 2022
Clinical Pearl of the Day: Generalized Anxiety Disorder
Author(s)Saro Arakelians, PharmD
Generalized anxiety disorder has symptoms that are similar to panic disorder, obsessive-compulsive disorder, and other types of anxiety.
Advertisement
Clinical Pearl of the Day: Generalized Anxiety Disorder (GAD)
Patients with GAD experience continuous anxiety and stressful life experience.
Insight:
- It's possible to develop GAD as a child or an adult.
- GAD has symptoms that are similar to panic disorder, obsessive-compulsive disorder, and other types of anxiety, but they're all different conditions.
- Living with generalized anxiety disorder can be a long-term challenge.
- In many cases, GAD occurs along with other anxiety or mood disorders.
- In most cases, GAD improves with psychotherapy or medications.
- Symptoms may include persistent worrying, overthinking, indecisiveness, inability to relax, and difficulty concentrating.
- Risk factors may include genetics and life experiences.
- Diagnosis may include physical therapy and mental assessment.
- Treatment includes psychotherapy, antidepressants, buspirone, and benzodiazepines.
- Making lifestyle changes, learning coping skills, and using relaxation techniques also can help.
Sources:
Advertisement
Related to this article
Mounjaro becomes the first GIP/GLP-1 receptor agonist cleared to lower MACE risk, based on the SURPASS-CVOT head-to-head trial.
Sea buckthorn is a commonly used herbal for respiratory health—US pharmacists are knowledgeable in educating patients on herbals, especially during the cold season.
Community pharmacies are access points, safe places, and sources of stability when everything else feels uncertain.
In the phase 3 B-Well trials, about 1 in 5 adults reached functional cure after a fixed course, but a boxed warning makes monitoring key for pharmacists.
Impostor syndrome prevalence in oncology pharmacists is a complex topic that is not well described.
The once-nightly drop, previously approved to reverse pupil dilation, met its primary end point in 2 phase 3 trials, with conjunctival hyperemia most common.
Isatuximab on-body injector enables quick, hyaluronidase-free subcutaneous dosing, reducing reactions and easing multiple myeloma clinic workflows.
Advertisement
Advertisement
Trending on Pharmacy Times
1
FDA Approves Bepirovirsen, First ASO for Chronic Hepatitis B
2
Operationalizing Therapy and Managing Hypophosphatemia Risk at UPMC
3
What Pharmacists Should Know About Sea Buckthorn for Respiratory Health
4
Can AI Help Predict Drug Shortages?
5